Home › Major Depressive Disorder › Washington
Major Depressive Disorder clinical trials in Washington
19 studies for Major Depressive Disorder are looking for participants at sites in Washington.
Cities in Washington
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
- Core Clinical Research, Everett
- Seattle Neuropsychiatric Treatment Center, Seattle
RecruitingPhase 3
Ages 18 to 85 · All sexes · Updated Nov 13, 2026 · NCT06793397A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
- Seaport Investigator Site, Everett
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Nov 10, 2026 · NCT07065240A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
- Seattle Neuropsychiatric Treatment Center, Seattle
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Nov 9, 2026 · NCT07592689A Study of Brenipatide in Adult Participants With Major Depressive Disorder
- Northwest Clinical Research Center, Bellevue
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Nov 4, 2026 · NCT07412756Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- Core Clinical Research, Everett
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Nov 3, 2026 · NCT06559306A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
- Northwest Clinical Research Center, Bellevue
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Nov 3, 2026 · NCT07775300Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- Northwest Clinical Research Center, Bellevue
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Nov 3, 2026 · NCT05850689A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
- Northwest Clinical Research Center, Bellevue
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Nov 3, 2026 · NCT07573176Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
- Core Clinical Research, Everett
RecruitingPhase 2
Ages 18 to 70 · All sexes · Updated Oct 28, 2026 · NCT07226661Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression
- VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Oct 23, 2026 · NCT07226232A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
- Draig Clinical Site, Bellevue
- Draig Clinical Site, Seattle
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Oct 14, 2026 · NCT07610473A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
- Draig Clinical Site, Bellevue
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Oct 8, 2026 · NCT07300969Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
- Vanda Investigational Site, Bellevue
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Sep 24, 2026 · NCT06830044Positive Processes and Transition to Health (PATH)
- University of Washington, Seattle
Recruiting
Ages 18 to 65 · All sexes · Updated Aug 19, 2026 · NCT06093906A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
- Northwest Clinical Research Center /ID# 277484, Bellevue
- Core Clinical Research /ID# 277518, Everett
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Jun 15, 2026 · NCT07276997Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
- Autobahn Site #143, Bellevue
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Jan 20, 2026 · NCT06633016Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Everett
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 29, 2025 · NCT06786624A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
- Clinical Research Site, Everett
RecruitingPhase 4
Ages 18 to 65 · All sexes · Updated Jan 23, 2025 · NCT06223880InMotion - Telehealth Delivered Exercise Promotion to Treat Major Depression After TBI
- University of Washington Medical Center, Seattle
Recruiting
Ages 18 to 64 · All sexes · Updated Sep 19, 2024 · NCT06005194From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.